The Limited Times

Now you can see non-English news...

Glyphosate scandal and health crisis: Bayer sinks into the red

2020-08-04T07:01:24.399Z


The German chemicals group on Tuesday reported a net loss of 9.5 billion euros in the second quarter.The German chemicals group Bayer on Tuesday reported a significant net loss in the second quarter, weighed down by the agreement signed in June in the United States to settle the procedures against glyphosate, and by the Covid-19 pandemic, which l 'led to lowering its forecasts for 2020. Read also: Has the use of glyphosate substantially decreased? Bayer reports a significant net loss of 9.5 bil...


The German chemicals group Bayer on Tuesday reported a significant net loss in the second quarter, weighed down by the agreement signed in June in the United States to settle the procedures against glyphosate, and by the Covid-19 pandemic, which l 'led to lowering its forecasts for 2020.

Read also: Has the use of glyphosate substantially decreased?

Bayer reports a significant net loss of 9.5 billion euros in the second quarter of 2020, against a profit of 404 million euros in the same period in 2019. This sharp drop is notably the result of " the effect exceptional "caused by" the major agreement reached within the framework of the proceedings against Monsanto ", indicates the group in a press release.

The company has resolved to sign an agreement in June between 8.8 and 9.6 billion dollars to settle more than 125,000 claims in the United States against Round'up, a glyphosate-based pesticide marketed by its subsidiary Monsanto , bought in 2018. The American plaintiffs accused this pesticide, suspected of being carcinogenic by the Circ, a branch of the WHO, to have caused the disease from which they suffer.

Decreased 2020 targets

The Leverkussen group was also largely affected by the pandemic, which plagued its activities in the second quarter, after having had a positive effect in the first quarter. Bayer saw a decrease in its adjusted revenue of 2.5% to 10.7 billion euros. The pharmaceutical division, with an operating loss (EBITDA) of 7.1%, was particularly affected. " The contact restriction measures introduced all over the world because of the coronavirus pandemic, have led to the [...] postponement of many treatments ", comments the group to explain this decline. The agrochemicals division, the engine of the group's growth in recent quarters, nevertheless reports an increase in its turnover corrected for currency and market effects of 3.2%.

The Covid-19 pandemic has led the group to revise its 2020 objectives downwards: Bayer now forecasts a turnover " between 43 and 44 billion ", while it expected " between 44 and 45 billion " previously, in February latest.

Source: lefigaro

All business articles on 2020-08-04

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.